Drug Profile
Tapentadol immediate release - Grunenthal
Alternative Names: BN-200; CG-5503; Nucynta; Palexia; R-331333; Tapentadol HCl immediate release; Tapentadol hydrochloride; Tapentadol IR; Tapentadol OSLatest Information Update: 29 Feb 2024
Price :
$50
*
At a glance
- Originator Grunenthal
- Developer Collegium Pharmaceutical; Grunenthal; Janssen Research & Development; Ortho-McNeil
- Class Amines; Opioid analgesics; Phenols; Small molecules
- Mechanism of Action Opioid mu receptor agonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Marketed Pain
- Phase III Postoperative pain
Most Recent Events
- 24 Aug 2023 Registered for Pain (In children) in USA prior to August 2023 (PO)
- 29 Nov 2022 No development reported - Phase-II for Pain (In children) in Poland (PO) (Grunenthal pipeline; November 2022)
- 06 Aug 2020 Grunenthal completes a phase II trial for Pain (In children) in Poland (PO,Liquid) (EudraCT2019-000205-77)